| 7.26 0.45 (6.61%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.52  |
1-year : | 9.95 |
| Resists | First : | 7.29 |
Second : | 8.52 |
| Pivot price | 6.36 |
|||
| Supports | First : | 6.42 |
Second : | 5.88 |
| MAs | MA(5) : | 6.7 |
MA(20) : | 6.26 |
| MA(100) : | 5.98 |
MA(250) : | 5.77 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 85.1 |
D(3) : | 84.2 |
| RSI | RSI(14): 86.8 |
|||
| 52-week | High : | 7.88 | Low : | 3.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TENX ] has closed above the upper band by 19.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 151.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.31 - 7.34 | 7.34 - 7.36 |
| Low: | 6.74 - 6.77 | 6.77 - 6.8 |
| Close: | 7.21 - 7.26 | 7.26 - 7.3 |
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Sat, 27 Sep 2025
We Think Tenax Therapeutics (NASDAQ:TENX) Can Afford To Drive Business Growth - simplywall.st
Tue, 16 Sep 2025
Tenax Therapeutics Secures European Patent Protection for TNX-103 and Levosimendan Formulations Until December 2040 - Quiver Quantitative
Tue, 16 Sep 2025
Tenax Therapeutics Announces European Patent Office - GlobeNewswire
Tue, 16 Sep 2025
European Patent Office to Grant 17-Year Protection: Tenax's Breakthrough Heart Failure Drug TNX-103 - Stock Titan
Tue, 16 Sep 2025
Tenax Therapeutics (TENX) Secures European Patent for PH-HFpEF Treatment - GuruFocus
Thu, 28 Aug 2025
Phase 3 Cardiopulmonary Drug Developer Tenax Therapeutics Featured at Major Healthcare Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 64.8 (%) |
| Shares Short | 298 (K) |
| Shares Short P.Month | 335 (K) |
| EPS | 2.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -37.7 % |
| Return on Equity (ttm) | -56.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | 2.46 |
| PEG Ratio | 0 |
| Price to Book value | 2.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.67 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|